Astria Therapeutics Inc ATXS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Astria Gets FDA Orphan Designation for Navenibart in Hereditary Angioedema
-
Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema
-
Astria Therapeutics to Present at Upcoming Global Angioedema Forum
-
Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress
-
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Astria Therapeutics to Participate in Upcoming Morgan Stanley 22nd Annual Global Healthcare Conference
-
Astria Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
-
Astria Therapeutics Chooses Ypsomed’s YpsoMate as the Injection Device for STAR-0215 for the Treatment of Hereditary Angioedema
Trading Information
- Previous Close Price
- $11.13
- Day Range
- $11.13–11.56
- 52-Week Range
- $4.27–16.87
- Bid/Ask
- $11.14 / $11.21
- Market Cap
- $630.83 Mil
- Volume/Avg
- 91,595 / 399,353
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 59
- Website
- https://www.astriatx.com
Comparables
Valuation
|
Metric
|
ATXS
|
BPMC
|
EXEL
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 17.02 |
Price/Book Value | 2.43 | 18.25 | 3.49 |
Price/Sales | — | 16.00 | 3.97 |
Price/Cash Flow | — | — | 16.25 |
Price/Earnings
ATXS
BPMC
EXEL
Financial Strength
|
Metric
|
ATXS
|
BPMC
|
EXEL
|
|---|---|---|---|
Quick Ratio | 21.67 | 3.48 | 4.05 |
Current Ratio | 21.87 | 3.71 | 4.27 |
Interest Coverage | — | −8.43 | — |
Quick Ratio
ATXS
BPMC
EXEL
Profitability
|
Metric
|
ATXS
|
BPMC
|
EXEL
|
|---|---|---|---|
Return on Assets (Normalized) | −24.27% | −24.11% | 14.82% |
Return on Equity (Normalized) | −39.29% | −104.04% | 19.05% |
Return on Invested Capital (Normalized) | −30.47% | −41.57% | 14.99% |
Return on Assets
ATXS
BPMC
EXEL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Knrglcdzfv | Lbh | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Zxjzmrlk | Jrgbpdg | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Rjvtlcwn | Jpsfrvx | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Wnmtsdpn | Hyfztd | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Lthmfvhtd | Smf | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Pbzjyfvy | Wygxm | $28.1 Bil | |||
| Moderna Inc
MRNA
| Srpynqdx | Mjxd | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Qmsnrjhr | Jzvz | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Mhwgznkcr | Syxsmqg | $13.4 Bil | |||
| Incyte Corp
INCY
| Shqcnsw | Rntrnm | $12.7 Bil |
United States